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Introduction
Interest in the role of accelerated partial breast irradiation 
(APBI) in the management of breast cancer has been 
growing. The rationale behind this approach is that the 
majority of local recurrences in the breast occur in the index 
quadrant whether radiotherapy is given or not. Therefore, 
“occult cancers” in other quadrants are probably not the 
cause of local recurrence and radiotherapy to the index 
quadrant alone maybe sufficient. The aim of APBI is to 
decrease the volume of breast irradiated whilst increasing 
the dose per fraction (hypofractionation).
A number of different techniques can be used for 
partial breast irradiation, including linear accelerator 
(LINAC)-based intensity modulated radiotherapy, 
interstitial brachytherapy, MammoSite and intra-operative 
radiotherapy (IORT). Although similar in principle, these 
techniques have large difference in dose rate and dose 
distribution, and are therefore not strictly comparable. 
IORT as a treatment for breast cancer is a relatively new 
method of delivering APBI that aims to replace whole 
breast external beam radiotherapy (EBRT) in selected 
women suitable for breast-conserving therapy.
IORT is possible because the development of mobile 
radiotherapy systems provides clinicians with the ability to 
readily provide treatment during the surgical intervention, 
as these systems can be taken into the operating rooms 
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and used to irradiate the tumour bed immediately after 
the breast tumour (and surrounding margin of healthy 
tissue) has been removed. Mobile instruments include 
brachytherapy treatments using sealed sources (i.e., HDR), 
electron units (Mobetron, Novac-7) and photon units 
(Intrabeam™).
Targeted intraoperative radiotherapy (TARGIT) is a 
simple and straightforward IORT technique, the success 
of which depends on attention to detail and collaboration 
between the multidisciplinary team of surgeons, radiation 
oncologists, physicists, radiotherapy technicians and 
operating theatre and nursing staff. In brief, after excision of 
the tumour and a margin of healthy tissue, the tumour bed 
is mobilised to ensure that there is at least 5 mm distance 
between the surface of the applicator and the skin, in order 
to reduce the risk of radionecrosis. The equipment used is 
the Intrabeam™ system (Carl Zeiss Surgical, Oberkochen, 
Germany) which is a mobile, miniature X-ray generator 
where accelerated electrons strike a gold target at the tip 
of a 10 cm long drift tube resulting in the emission of low 
energy X-rays (50 kV) in an isotropic dose distribution. The 
irradiated tissue is kept at a fixed distance from the source by 
a spherical applicator to ensure a uniform dose distribution. 
A variety of sizes of applicators are available to fit the size of 
the surgical cavity; the dose rate depends on the diameter of 
the applicator with larger applicators requiring more time to 
deliver the dose of 20 Gy to the surface. Treatment times are 
typically between 20 to 45 minutes depending on the size 
of the applicator used. There is a steep attenuation of the 
radiation which allows the treatment to be safely carried out 
in unmodified operating theatres.
This article reviews twelve reasons for the use of IORT 
as treatment for breast cancer, with a particular emphasis on 
TARGIT. 
Historical trends 
EBRT is a safe and effective treatment after breast-
conserving surgery, which reduces the in-breast recurrence 
rate by two-thirds (1) and the breast cancer death rate by 
about a sixth (2). However, with few exceptions, EBRT 
has been given to the entire breast. This is in contrast 
to surgery which has moved from radical (mastectomy) 
to minimal (lumpectomy) (3), but radiotherapy remains 
radical (whole breast), even though the results of many 
observational studies and clinical trials have demonstrated 
that around 90% of recurrent disease in the breast after 
breast conserving surgery is within the index quadrant, 
whether or not whole-breast EBRT has been given (4). 
Furthermore, after adjuvant endocrine therapy, the chance 
of a local recurrence outside the index quadrant is no more 
than the risk of a new contralateral tumour (5).
Timeliness of radiotherapy
Usually, EBRT is given several weeks after surgery, or 
several months if chemotherapy is also given. Several 
large population studies have shown that long intervals 
between breast conserving surgery and EBRT could be 
associated with inferior outcomes (6-8). By contrast, giving 
radiotherapy during primary surgery avoids any delay and 
may have beneficial biochemical effects that are important 
during the wound healing that occurs during recovery from 
surgery. 
Evidence from translational research has found that 
treatment with TARGIT alters the molecular composition 
and biological activity of wound fluid in the tumour bed, 
which impairs the surgical trauma-stimulated proliferation 
and invasiveness of cultured breast cancer cells (9). Further 
work by the same group has found that treatment using the 
TARGIT technique modulates expression of microRNA 
that in turn modifies the expression of two growth factors 
known to be important in the regulation of cancer cell 
growth and motility, which may help to prevent local 
recurrences in early breast cancer (10).
Supported by level-one evidence
The international multicentre TARGIT A randomised 
controlled trial (ISRCTN34086741) was designed to 
determine non-inferiority between the TARGIT technique 
and conventional external beam radiotherapy (EBRT) in 
women with early breast cancer. IORT is given as a single 
dose of 20 Gy at the surface of the applicator (equivalent to 
6 Gy at 1 cm) delivered directly to the tumour bed under 
direct observation. The primary outcome measure is local 
relapse within the treated breast; secondary endpoints are 
site of relapse within the breast, relapse-free and overall 
survival, and local toxicity/morbidity (11). The 5-year risk 
for local recurrence in the conserved breast when TARGIT 
was given concurrently with lumpectomy (n=2,298) had 
much the same results as EBRT: 2.1% (1.1-4.2) vs. 1.1% 
(0.5-2.5; P=0.31) (12).
A method of delivering IORT with electrons (instead 
of photons) has also reported results from a randomised 
controlled trial performed at the European Institute of 
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Oncology (Milan, Italy). The results showed much poorer 
local control with this type of IORT when compared with 
EBRT: 35 patients in the IORT group and four patients in 
the external radiotherapy group had an ipsilateral breast 
tumour recurrence (P<0.0001). The 5-year event rate 
for IBRT was 4.4% [95% confidence interval (CI), 2.7-
6.1] in the IOPT group and 0.4% (0-1.0) in the external 
radiotherapy group [hazard ratio 9.3 (95% CI, 3.3-
26.3)] (13). This technique of delivering IORT, which 
is superficially similar to TARGIT, is in fact different in 
several important respects. Perhaps the most significant 
drawback of electron beam therapy is the inability to 
incorporate a risk-adjusted approach of giving EBRT after 
IORT to patients with additional risk factors. In the ELIOT 
trial, most of the local recurrences occurred in patients 
with disease characteristics suggesting subsequent use of 
whole breast irradiation (tumour >2.0 cm or ≥4 positive 
nodes or grade 3 or triple negative); patients without these 
characteristics had a much lower risk of local recurrence 
(1.7% 5-year event rate). There may therefore be a role for 
the Milan techniques of IORT using electrons during breast 
conserving surgery in a carefully selected population at low 
risk of local recurrence (14).
Regarding safety in the ELIOT study, information about 
side-effects of radiotherapy was available for 464 and 412 
patients in the IORT group and EBRT group, respectively. 
Overall, skin side-effects showed a significant difference in 
favour of the IORT group (P=0.0002), with significantly 
reduced rates of erythema (P<0.0001), dryness (P=0.04), 
hyper-pigmentation (P=0.0004), and pruritus (P=0.002). 
The rate of fat necrosis was worse in the IORT group 
(P=0.04). In contrast, the TARGIT A trial reported that 
the frequency of any complications and major toxicity was 
similar in the IORT and EBRT groups [for major toxicity, 
TARGIT, 37 (3.3%) of 1,113 vs. EBRT, 44 (3.9%) of 
1,119; P=0.44]. Radiotherapy toxicity (Radiation Therapy 
Oncology Group grade 3) was lower in the TARGIT group 
[six patients (0.5%)] than in the EBRT group [23 patients 
(2.1%); P=0.002] (15).
Two randomised trials of external partial breast 
irradiation (16,17) have not shown this technique to be 
an effective form of local control. A third trial (18), with a 
strict selection of patients, reported non-inferiority between 
partial and whole breast irradiation in terms of local 
control and survival after a median follow up of 10 years. 
A meta-analysis of partial breast irradiation (19) showed an 
increased risk for both local and regional recurrence with 
partial breast irradiation, with no survival difference, when 
compared with whole breast irradiation.
Risk-adaptive technique
It should be pointed out that IORT cannot always be given, 
even in women who meet the eligibility criteria. A study in 
Germany of 297 women found that in 55 women (19%) the 
planned IORT was not performed, mainly due to reasons 
which became apparent during surgery, namely: insufficient 
tumour-skin distance (n=20, 35.1%), an oversized wound 
cavity (n=14, 24.6%), and a combination of both (n=8, 14%) (20). 
In such cases, and in patients who have been given IORT, 
it is always possible to treat with EBRT at a later date, with 
omission of the tumour bed boost (if IORT has been given). 
This is why the technique is called “risk-adaptive”. Note 
that in such cases the patients do not “lose” anything, apart 
from a few more minutes under anaesthesia.
The replacement of the EBRT boost to the tumour bed 
by a TARGIT boost given during surgery is being tested in 
TARGIT-B (for boost, ISRCTN43138042), a multicentre 
randomised controlled trial that began accrual in 2013 (21). All 
patients will receive EBRT. The target population is patients 
with breast cancer who have a high risk of local recurrence. 
Specifically, patients should be either younger than 45 or, if 
older, need to have pathological features that confer a high risk 
of local recurrence of breast cancer, such as lymphovascular 
invasion, gross nodal involvement (not micrometastasis), more 
than one tumour in the breast but still suitable for breast-
conserving surgery through a single specimen, ER negative, 
grade 3 histology or positive margins at first excision. This 
trial is based on results from a phase II non-randomised study 
in 299 unselected patients who had breast-conserving surgery 
and TARGIT as a boost to the tumour bed as a single dose 
of 20 Gy delivered intraoperatively. Postoperative external 
beam whole-breast radiotherapy excluded the usual boost. 
The treatment was well tolerated. After a median follow up of 
60.5 months, eight patients had an ipsilateral recurrence, 
which gave a 5-year Kaplan-Meier estimate for ipsilateral 
recurrence of 1.73% (SE 0.77) (22). This therefore justifies the 
“risk adaptive” approach.
Reduced irradiation of normal tissues
In addition to the avoidance of irradiation of skin, the 
rapid attenuation of IORT X-rays means there is much 
less radiation exposure to normal tissues. An estimate was 
made of secondary cancer risks after IORT compared to 
APBI and EBRT by using computer-tomography scans of 
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an anthropomorphic phantom with an Intrabeam™ IORT 
applicator in the outer quadrant of the breast; the scans 
were then transferred to a treatment planning system. 
For normal tissues, the maximal doses were calculated 
and lifetime risk for secondary cancers estimated. IORT 
delivered the lowest maximal doses to contralateral breast 
(<0.3 Gy), ipsilateral (1.8 Gy) and contralateral lung (<0.3 Gy), 
heart (1 Gy) and spine (<0.3 Gy). In comparison, maximal 
doses for APBI were 2-5 times higher. EBRT delivered 
a maximal dose of 10.4 Gy to the contralateral breast 
and 53 Gy to the ipsilateral lung. The estimated risk for 
secondary cancer was considerably lower after IORT and/or 
APBI as compared to EBRT (23).
Darby et al. (24) recently conducted a population-
based case–control study of major coronary events (such 
as myocardial infarction, coronary revascularization, or 
death from ischemic heart disease) in women who received 
radiotherapy for breast cancer between 1958 and 2001. 
For each woman, the mean radiation dose to the heart was 
estimated. The overall average of the mean dose to the 
whole heart was 4.9 Gy; rates of major coronary events 
increased by 7.4% per gray (95% CI, 2.9 to 14.5; P<0.001), 
with no apparent threshold. It was concluded that exposure 
of the heart to ionizing radiation during radiotherapy 
increased the subsequent rate of ischemic heart disease. 
Brenner et al. (25) then performed a similar study on 
women exposed to contemporary (2005 and later) EBRT, 
and found a mean cardiac dose of 1.37 (95% CI, 1.12-1.61) Gy, 
less than one-third that found by Darby et al. However, 
the highest estimated radiotherapy-induced lifetime risks 
were still significant [3.52% (95% CI, 1.47-5.85%)]. It 
therefore seems that, even with modern radiotherapy 
planning techniques, EBRT can deliver an undesirable dose 
of radiation to the heart.
There is no question that TARGIT delivers less 
radiation to normal tissues. This has been demonstrated 
using a biological marker of radiation dose (gamma-H2AX 
in circulating lymphocytes) where it was shown that the 
DNA damage caused by X-radiation was significantly less 
with TARGIT compared with EBRT (26).
Better cosmetic outcome
The use of IORT has been shown to result in better cosmetic 
outcome when compared with EBRT (27) using an objective 
evaluation of aesthetic outcome. Frontal digital photographs 
were taken at baseline (before TARGIT or EBRT) and 
annually thereafter for up to 5 years. The photographs were 
analysed by a validated, specialised software application that 
produces a composite score (Excellent, Good, Fair, Poor) 
based on symmetry, colour and scar. There was a statistically 
significant increases in the odds of having an outcome of 
Excellent or Good for patients in the TARGIT group relative 
to the EBRT group at year 1 [odds rate (OR) 2.07, 95% CI, 
1.12-3.85, P=0.021] and year 2 (OR 2.11, 95% CI, 1.0-4.45, 
P=0.05). This study demonstrated that women treated with 
TARGIT had a superior cosmetic result compared with 
patients who received conventional EBRT.
The cosmetic effects of breast conservation therapy have 
been studied for decades, but the usual methods for evaluating 
cosmetic outcome are assessments made by the clinical care 
team, including the surgeon who performed the operation. 
Although this is an important source of feedback, such 
information is obviously biased and cannot be used reliably 
to compare techniques carried out by different clinicians, 
perhaps at different centres, using different techniques. Some 
researchers utilise a blinded assessment of outcome, usually by 
an independent panel examining photographs, but this is time 
consuming and too cumbersome to be used in routine practice.
There are few published studies on the measurement of 
cosmesis after IORT. In the MSKCC Series (28), where 
quadrant IORT of 18-20 Gy was given, the cosmetic 
outcome was acceptable. In the Montpellier phase II 
trial (29) IORT was given as electrons (21 Gy); at a median 
follow-up of 30 months of 94 patients, all showed excellent 
or good cosmesis. In a study of IORT using Axxent, a 
balloon-based electronic brachytherapy (20 Gy), at median 
follow-up of 12 months there was excellent cosmesis in 10 
of the 11 patients (30). However, an interim report from a 
large randomised controlled trial found that APBI increased 
rates of adverse cosmesis (and late radiation toxicity) 
compared with EBRT (31).
Economically viable
The institutional perspective
An economic evaluation of new treatments is a key part 
of a health technology assessment, as resources are finite. 
Appleby has shown that, in the past 30 years, total national 
expenditures on healthcare as a percentage of gross 
domestic product (GDP) have increased. In the UK this 
figure rose from 3.9% in 1960 to 9.4% in 2010, in Germany 
it rose from 6.0% in 1970 to 11.6% in 2010 and in the US 
from 5.1% in 1960 to 17.6% in 2010 (32).
The population is ageing; the demand on LINAC units 
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for treatment of breast cancer is approximately a third of 
the workload in the UK, and rising, putting an increasing 
burden on radiotherapy infrastructure. For IORT, one 
consideration is the capital cost to purchase the required 
equipment, which is at least one-tenth of that required for a 
LINAC capable of delivering EBRT. This is without taking 
into account the requirements for shielding the LINAC 
(which usually requires significant amounts of shielding, 
often in the form of a “concrete bunker”); with TARGIT, 
minimal shielding is required in the operating theatre (33). It 
might be argued that as the institution has already invested 
in the LINAC, it might as well use it. However, workload 
on radiotherapy departments is increasing, so alternative 
methods of delivering radiotherapy should be considered, 
particularly those that are safe, efficacious, and cost-
effective. 
A Markov decision-analytic model developed in the USA 
has shown that significant cost savings are possible when 
using TARGIT even if only a small proportion of women 
with early breast cancer are offered IORT as opposed to 
EBRT (34). IORT single-dose intraoperative radiation 
therapy was the more cost-effective strategy, providing 
greater quality-adjusted life years at a decreased cost. The 
authors concluded that IORT offers a unique example of new 
technology that is less costly than the current standard of 
care option but offers similar efficacy; the capital investment 
for the equipment could be recouped after 3-4 years.
However, Shah et al. (35), using cost-minimization 
analyses, compared intra-operative radiation therapy 
(IORT) with whole-breast  irradiation (WBI) and 
accelerated partial-breast irradiation (APBI) and concluded 
that APBI and WBI are cost-effective compared with IORT. 
This was partially due to the level of reimbursement paid in 
the USA for these treatments. 
Another economic consideration is the additional 
time required in the operating theatre for delivery of the 
radiation. In some circumstances, this can be offset by using 
this time for the intraoperative testing of the histological 
status of the sentinel lymph nodes, as most patients who 
undergo IORT also require sentinel node biopsy. An 
example is the one stage nucleic acid (OSNA) test. During 
administration of the IORT the sentinel lymph node is 
processed; by the end of treatment, the result of the OSNA 
test has been received and further surgery can be performed 
if required. It is therefore possible for a woman to have 
complete removal of the tumour, clearance of the axilla (if 
necessary), and radiotherapy all in a single session.
Another economic argument is that the IORT equipment 
can be used for applications other than breast cancer, such as 
treatment during kyphoplasty for vertebral metastases (36), 
or to deliver intravaginal radiotherapy (37).
Societal perspective
This perspective is wide and explores costs and benefits 
borne by all. The IORT equipment does not need to 
be based in a radiotherapy centre; it can be used in any 
operating theatre. Also, IORT is given as a single fraction, 
and does not require daily visits over three to five weeks. 
These factors mean that patients may have reduced travel 
time for treatment, and reduced time off work (or as 
primary carers for family). A large study in the USA found 
that women traveling over 75 km for treatment are about 
1.4 times more likely to receive a mastectomy than those 
traveling under 15 km (38). 
These factors need to be further explored to tease out not 
only costs saved by patients due to reduced travel time and 
reduced time off work, but also to interrogate the effects 
of shifting radiotherapy burden away from radiotherapy 
centres and into surgical theatres, effects on income tax, 
works and pensions, savings to families and employers, and 
effects on private insurance premiums and claims. A full 
assessment would yield a “treasure trove” of information.
Excellent patient preference and satisfaction
A study in the USA (39) used a trade-off technique to vary 
the risk of local recurrence for IORT and quantify any 
additional hypothetical 10-year local recurrence risk that 
patients would accept to receive either IORT or EBRT. 
Data from 81 patients showed that the median additional 
accepted risk to have IORT was 2.3% (from 9% to 39%), 
mean 3.2%. These results demonstrate that the majority of 
women with breast cancer will accept a small increment of 
local risk for a simpler delivery of radiation. 
A study in Australia compared preferences of women 
after they had received either IORT or EBRT. There was 
discordance in the willingness of patients to accept additional 
risk; the patients who had received EBRT were risk-
averse, whilst patients who had received IORT valued the 
convenience of this treatment: 60% of them would accept an 
additional risk of recurrence as high as 4% to 6% (40).
Better quality of life
It should be noted that although patient-reported outcome 
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measures are increasingly used and quality of life is a key 
measure of clinical effectiveness, the measures used fall short 
of those required for evidence-based medicine. A review of 
227 outcome studies for aesthetic and reconstructive breast 
surgery found only one study that was validated, specific and 
reproducible (41). The use of objective measurement of the 
patient’s perception and expectations is needed to assist in 
the development of accurate predictive tools to better enable 
clinicians and patients to choose the optimal treatment.
It has been demonstrated in Germany that women who 
received IORT had superior radiation-related quality of 
life parameters compared with those who have EBRT (42). 
A single-centre subgroup of 87 women from the two arms 
of the randomized controlled TARGIT-A trial found that 
patients receiving IORT alone reported less general pain, 
fewer breast and arm symptoms, and better role functioning 
than patients receiving EBRT (P<0.01). 
Quality of life has also been reported to be high during/
after MammoSite breast brachytherapy (43).
IORT can be given to a previously irradiated breast
It is possible to apply IORT to a breast that has already been 
exposed to whole-breast EBRT, provided that the woman 
is suitable for a second breast-conserving procedure (44). 
This means that such women can be given an alternative to 
salvage mastectomy.
Furthermore,  there is  l imited but encouraging 
experience of giving IORT twice within the same breast, for 
the primary cancer and a subsequent new primary cancer in 
another quadrant that developed some years later (H Flyger, 
Denmark, personal communication).
IORT can be given to women who would not be 
given EBRT
There are women who present with special circumstances 
who would never be considered for EBRT and for whom 
mastectomy is the only option; such as those who are frail 
and elderly, or who have Parkinson’s Disease, or who have 
a cardiac pacemaker, or have collagen vascular disease. A 
study performed on a group of such patients has shown 
that IORT is an option that should be considered in 
such patients (45). Thirty-one patients were treated with 
TARGIT due to clinical reasons for not receiving EBRT 
such as systemic lupus erythematosus, motor neuron 
disease, Parkinson’s disease, ankylosing spondylitis, morbid 
obesity, and cardiovascular or severe respiratory disease. A 
further 28 patients were included for compelling personal 
reasons, usually on compassionate grounds. After a median 
follow-up of 38 months, only two local recurrences were 
observed, an annual local recurrence rate of 0.75% (95% 
CI, 0.09-2.70%). This evidence suggests that TARGIT is an 
acceptable option in highly selected cases in whose EBRT is 
not feasible or possible.
The influence of age on short-term complications in 
women undergoing IORT for early breast cancer was 
investigated in a retrospective study of 188 women who 
underwent IORT during breast-conserving surgery and 
found that acute toxicity after IORT in women aged 70 years 
and older was not higher compared to younger patients (46).
TARGIT-E (for elderly) is a single-arm trial on use 
of TARGIT in elderly patients being run in Mannheim 
by Professor Frederik Wenz. The protocol is based on 
the international TARGIT-A study. The purpose is to 
investigate the efficacy of a single IORT treatment within 
elderly low-risk patients (≥70 years, cT1, cN0, cM0, 
invasive ductal carcinoma) which is followed by EBRT only 
when adverse risk factors are present (47).
TARGIT Academy
Although the TARGIT IORT technique is relatively 
straightforward, the success of this technology requires 
adequate training and attention to detail. The lessons 
learned from the introduction of new surgical techniques in 
surgery in the past have been appreciated and incorporated 
into a unique training scheme. 
The TARGIT Academy was established in 2010 and 
is co-directed by Professor Mo Keshtgar from the Royal 
Free and University College London, UK and Professor 
Frederik Wenz from the University Medical Centre 
Mannheim & University of Heidelberg. The remit of the 
TARGIT Academy is to offer high quality training together 
with the opportunity to gain access to a broad academic 
network. The faculty are from a variety of disciplines, many 
of whom have been involved with this technology from 
the outset. Some of the trainers have extensive experience 
in performing the procedure and can provide “first hand” 
advice for difficult cases that are seen occasionally. Regular 
training courses are run in London and Mannheim and are 
sponsored by the manufacturer of the Intrabeam™ (Carl 
Zeiss Surgical, Oberkochen, Germany).
The foundation of  the TARGIT Academy is  a 
networking platform, which enables interaction and 
cooperation between surgeons, radiation oncologists, 
115Gland Surgery, Vol 3, No 2 March 2014
© Gland Surgery. All rights reserved. Gland Surgery 2014;3(2):109-119www.glandsurgery.org
m e d i c a l  p h y s i c i s t s  a n d  o t h e r  m e m b e r s  o f  t h e 
multidisciplinary team. As the success of this technique 
depends on multidisciplinary team working harmoniously 
with each other, the training is available only to teams and 
not individuals. At the outset it was felt important that the 
entire team should listen to some of the detailed specialist 
instructions so that they can appreciate the roles of their 
colleagues more fully. For example, many of the surgeons 
will be unfamiliar in the use and handling of the IORT 
device, selection of an appropriate applicator and adequate 
placement in the tumour bed; it is important that the entire 
team are aware of these “surgical” details, as they can have a 
bearing on other aspects of patient management.
The UK Newstart sentinel node biopsy training 
programme (48) has been used as a model for the TARGIT 
Academy. The training involves three phases: theory 
and hands on experience in a skills laboratory; proctored 
training; and an audit phase.
Theory and hands-on training
The TARGIT Academy offers participants a unique first 
hand education and intensive hands-on training, which 
accelerates the learning curve to the optimum level within 
shortest time. An extensive training course is run over two 
days, and is intended to provide peer-led training about 
proper selection of patients, current clinical trial results, the 
safe use of Intrabeam™ and the precise use of the TARGIT 
technique. There is also emphasis on the radiobiology and 
radiation safety aspects of this procedure to ensure correct 
guidelines are followed. As the indications for the use of 
TARGIT is expanding to other tumour sites, these new 
developments are also covered. At the end there is a group 
discussion, incorporating troubleshooting and presentations 
of interesting cases in a mock multidisciplinary meeting 
setting.
Educational material
The educational material comprises of full slide set of the 
training programme, a video recording of the procedure 
performed in the operating theatre, and a comprehensive 
reference list with copies of key publications. All participants 
receive a copy of a comprehensive textbook edited by the 
course organisers (49), which has recently been revised and 
updated (50).
The TARGIT training simulator
In order for the surgeons and the interdisciplinary team to 
be equipped with the appropriate practical skills required 
to perform the procedure, a bespoke training simulator, 
conceived by one of the authors (MK), has been designed 
and built, and is commercially available (51). This simulator 
accelerates the learning curve to the optimum level within 
the shortest time, as it is realistic anatomically, and is 
constructed from a hot-melt thermoplastic polymer with 
similar physical characteristics and radiation attenuation 
qualities to the human breast, which therefore allows an 
accurate demonstration of the technical aspects of TARGIT. 
Simulated tumours of different sizes and locations 
are implanted within the model to simulate a real life 
experience as far as possible. The polymer can be cut with 
a scalpel, and stitches applied. The design of the simulator 
is such that participants get an opportunity to practice the 
implementation of the entire treatment workflow. This is 
accompanied by an in-depth demonstration of the practical 
aspects by reviewing the recorded operative procedure on 
an actual patient (see Figures 1 and 2).
Proctored training
The Academy also facilitates proctored training for 
TARGIT naïve centres that have recently acquired the 
equipment. This is done by an experienced trainer and 
provides an opportunity for the extended multidisciplinary 
team including the operating theatre staff to familiarize 
Figure 1 Simulator for training in the TARGIT Academy. The 
Intrabeam with applicator has been placed into the tumour bed of 
the simulator, and a purse-stitch applied. TARGIT, targeted intra-
operative radiotherapy.
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themselves with the technical aspects of the procedure. 
In order to ensure that adequate numbers of trainers are 
available, a “training the trainer” programme is being 
designed and will commence soon.
Audit phase
Centres that intend to participate in one or more of the 
international TARGIT trials need to complete an audit 
phase by successfully performing five TARGIT procedures, 
followed by review and approval by the trial steering group. 
This ensures uniformity of practice within the participating 
centres in the trial.
TARGIT Academy website
A TARGIT Academy website (52) is an interactive, up-to-
date portal with both “open” and “closed sections which 
can only be accessed by the members of the academy. 
The intention is to develop a group discussion forum so 
that staff from centres all over the world can look up new 
information, or refresh their memories of information that 
they may have forgotten. All the educational materials and 
latest developments on TARGIT will be posted on the 
website for access by Intrabeam™ users.
There has been a significant interest in the TARGIT 
technique since the first publication of the results of the 
randomized controlled trial confirming its safety and 
efficacy. It is essential that as new centres take up this 
innovative technology worldwide, there is an adequate 
quality assurance and training program in place to ensure 
that this powerful technology is implemented appropriately. 
The establishment of the TARGIT Academy is a step 
towards achieving this objective.
Conclusions
Finally, it should be mentioned that TARGIT is the only 
IORT technique that is capable of delivering X-rays 
within the operating theatre, and is supported by level-
one evidence. In addition to the trials already mentioned, 
the following studies will continue to gather high-quality 
evidence for the effectiveness of the technique.
TARGIT-US (for United States) is a Phase IV Registry 
Trial being run in the USA through the University of 
California, San Francisco to study the efficacy and toxicity 
of breast radiotherapy given intraoperatively as a single 
dose after breast-conserving surgery, with or without whole 
breast radiation as indicated by pathological risk factors, in 
women with early stage breast cancer (53).
TARGIT-R (for registry, ISRCTN91179875) will be 
an open registry study with very wide inclusion criteria, 
enabling clinicians to treat patients with the TARGIT 
technique provided they have the support of their 
institution and colleagues. Data collection will be as per the 
existing TARGIT-A trial and is ideal for centres involved 
in this trial who wish to continue to treat patients now that 
randomisations have ceased (54).
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